文献速递MDS 与骨髓增殖性肿瘤

在体内描绘Jak2 V617F阳性骨髓增殖性肿瘤中依赖与不依赖Mpl的表型

Delineating Mpl-dependent and -independent phenotypes of Jak2 V617F-positive MPNs in vivo.
PubMed 文献 · Blood · 2025-01-01

研究采用在内源性启动子下以杂合状态表达Jak2 V617F的Mpl敲除小鼠模型,发现红细胞增多、白细胞增多及伴轻度脾周纤维化的中度脾肿大在缺乏Mpl时仍持续存在;Jak2 V617F对早期造血祖细胞的生长刺激效应在缺乏Mpl时保持一致,但在干细胞水平减弱且竞争性移植中不能克隆扩增。

要点

  • Mpl缺失时Jak2 V617F仍可驱动红细胞增多、白细胞增多和中度脾肿大伴轻度脾周纤维化。
  • Jak2 V617F对多种早期造血祖细胞的生长刺激效应在缺乏Mpl时保持一致。
  • Mpl缺失使Jak2 V617F在干细胞水平的效应减弱,竞争性移植中不能克隆扩增。

核心结论

  • Jak2 V617F可诱导依赖Mpl和不依赖Mpl的表型,在干细胞水平抑制Mpl表达可消除突变克隆的长期优势。
  • Mpl是Jak2 V617F阳性MPNs的主要参与者但并非唯一贡献者,这拓宽了治疗干预的范围。

研究设计与样本

  • 研究使用在内源性启动子下以杂合状态表达Jak2 V617F、并处于Mpl敲除背景的新型小鼠模型。

主要发现

  • 在缺乏Mpl表达时,红细胞增多、白细胞增多及伴轻度脾周纤维化的中度脾肿大仍持续存在。
  • Jak2 V617F诱导的固有生长刺激效应在缺乏Mpl时于多种早期造血祖细胞群体中保持一致。
  • 该生长刺激效应在干细胞水平减弱,且在竞争性移植中不能允许克隆扩增。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Jak2 V617F mutation stands as the main driver of myeloproliferative neoplasms (MPNs) by constitutively activating signaling through several type I cytokine receptors, namely the erythropoietin receptor, the thrombopoietin receptor (TpoR)/myeloproliferative leukemia (Mpl) protein, and the granulocyte colony-stimulating factor receptor. Among these, TpoR assumes a pivotal role in hematopoietic stem cell renewal and differentiation, being positioned as a key driver of MPNs alongside mutated Jak2. However, the impact of TpoR/Mpl absence in the context of Jak2 V617F in vivo has been explored only through a transgenic Jak2 V617F mouse model, in which regulation of Jak2 expression does not depend on its natural promoter. In this study, we use a novel mouse model expressing Jak2 V617F under its endogenous promoter at the heterozygous state within a Mpl knockout background. Our findings indicate that erythrocytosis, leukocytosis, and moderate splenomegaly with mild perivascular fibrosis of the spleen persist even in the absence of Mpl expression. Notably, the inherent growth-stimulating effect induced by Jak2 V617F remains consistent across diverse early hematopoietic progenitor populations in the absence of Mpl but is reduced at the stem cell level and does not allow clonal expansion in competitive transplantation. Our results delineate Mpl-dependent and -independent phenotypes induced by Jak2 V617F and confirm that inhibiting Mpl expression at the stem cell level negates the long-term advantage of the mutant clone. Consequently, although Mpl emerges as a major player in Jak2 V617F-positive MPNs, our study underscores that it is not the exclusive contributor, broadening the spectrum for therapeutic intervention.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Papadopoulos N, Nédélec A, Rahmani Y, et al. Delineating Mpl-dependent and -independent phenotypes of Jak2 V617F-positive MPNs in vivo. Blood. 2025. PMID: 40332017. doi:10.1182/blood.2024026711

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。